Managing patients who present late with HIV infection is challenging. All late-presenting patients should have an individual treatment plan that encompasses both antiretroviral therapy and, where necessary, treatment for opportunistic diseases. Timely initiation of treatment in late presenters is crucial but the optimal time to start therapy depends on many individual factors, including the presence of opportunistic infection and potential drug-drug interactions. Primary drug resistance is an important contributor to poor clinical outcomes in HIV; resistance profiling before treatment initiation is therefore recommended. The choice of initial HIV treatment should reflect patient characteristics, the results of resistance testing and the complexity of concomitant disease.
Managing patients who present late with HIV infection can be challenging. As has been explored elsewhere in this supplement by Moreno et al. [1] , the more advanced infection seen in late-presenting patients makes them more likely to experience HIV infection-and treatmentrelated morbidity, and increases their risk of mortality. These patients require more complex management that must take many factors into account, particularly the full spectrum of potential drug-drug interactions.
When should treatment be started?
All patients who present late with HIV infection (with CD4 + T-cell counts <350 cells/µl) should have their HIV disease status and comorbidities evaluated promptly, and an individual treatment plan should be developed that encompasses both antiretroviral therapy (ART) and, where necessary, treatment for opportunistic diseases [2] . Current guidelines for resource-rich settings recommend that all patients who present with a CD4 + T-cell count <350 cells/µl should receive treatment and that treatment should be considered for some patients who present above this threshold but with other indicators [3] [4] [5] [6] [7] .
Timely initiation of treatment is therefore crucial; however, the optimal time to start therapy in those presenting late depends on many individual factors, including the patient's willingness to start therapy, the presence of comorbidities (especially opportunistic infections) and possible drug interactions or overlapping toxicities [2] . In those with very late diagnosed advanced disease, immune reconstitution inflammatory syndrome (IRIS) might occur after initiation of ART, further complicating treatment [8] .
Opportunistic infection is common among latepresenting patients and can affect the timing of ART. When opportunistic infection is present, the optimal time to start ART varies depending on the type of infection. Primary prophylaxis should be started immediately. A randomized strategy trial of early ART (given within 14 days of starting acute opportunistic infection treatment) and deferred ART (given after acute opportunistic infection treatment is complete) supports the early initiation of ART in many patients with opportunistic infections [9] . The most common opportunistic infections among the 282 patients studied were Pneumocystis carinii pneumonia (63%), other bacterial infections (12%), cryptococcus infection (12%) and toxoplasmosis infection (5%); other infections recorded include histoplasmosis infection, cytomegalovirus infection and mycobacterium avian complex infection. Tuberculosis (TB) was excluded from the study because of envisioned drug-drug interactions Figure 1 ). Early improvement in immune responsiveness appears to be crucial in preventing clinical progression [9] . Other studies also suggest that starting ART sooner rather than later might reduce mortality and slow disease progression in many patients with opportunistic infections [10, 11] . In a South African study of patients with CD4
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+ T-cell counts <500 cells/µl, patients who received integrated ART and TB treatment had significantly lower mortality (hazard ratio 0.451, 95% confidence interval [CI] 0.26-0.79; P=0.0049) than those who started ART after completing TB treatment, regardless of CD4 + T-cell count [10] . On average, patients in the concurrent and sequential arms began ART 67 days and 261 days after starting TB treatment, respectively [10] . Nevertheless, there are concerns that early initiation of ART leads to IRIS and worsening of TB, particularly in patients with very low CD4 + T-cell counts [11, 12] . A study of 271 ART-naive patients in Uganda found that 16 (5.9%) patients developed active TB within 6 months of starting ART (early unmasking), whereas 13 of 45 patients with pre-existing TB displayed worsening of symptoms, signs and/or radiological features of TB [13] . Equally, a Vietnamese study of 253 patients randomized to receive either delayed or immediate ART found that the latter strategy offered no improvement in 9-month mortality, and significantly increased the number of severe adverse events in the first 2 months of treatment (P=0.04) [14] . The optimal timing for initiation of ART in patients with both HIV and TB remains unresolved [11] .
Other data suggest that caution is required with early initiation of ART in patients with certain types of infection. In an African study of patients with cryptococcal meningitis, early initiation of ART was associated with increased mortality compared with delaying ART until 10 weeks after initiation of fluconazole monotherapy [15] . Moreover, there is evidence that ART started at the time of or soon after diagnosis of malignancies, such as non-Hodgkin's lymphoma [16] or Kaposi's sarcoma [17] , might prolong survival; however, the regimen must be chosen carefully in order to avoid or minimize potential interactions with chemotherapy [18] .
Key clinical considerations
The benefits of immediate ART must be balanced against the risks of cumulative drug toxicity and drug-drug interactions [2, 7] . Being aware of the known interactions between ART and opportunistic infection therapy, and the possibility of adverse reactions, will affect the choice of initial therapy [19] .
Tolerability is important in patients presenting with low CD4 + T-cell levels because it might affect patient adherence. The potential for increased toxicities, transmitted resistance, central nervous system (CNS) disease and increased drug interactions when treating concurrent conditions, such as malignancies or opportunistic infections, all need to be considered when choosing an appropriate treatment regimen. Baseline CD4 + T-cell counts of <50 cells/µl at the initiation of nucleoside reverse transcriptase inhibitor (NRTI) therapy have been associated with an increased risk of peripheral neuropathy [20] . Similarly, in patients with baseline CD4 + T-cell levels <50 cells/µl, treatment-related adverse events, particularly diarrhoea and nausea, were more common in patients receiving lopinavir/ritonavir than in those receiving atazanavir/ritonavir [21] . Moreover, among patients with CD4 + T-cell counts <50 cells/ µl at baseline, 25% of those receiving lopinavir had discontinued by week 48, compared with 10% of those receiving atazanavir [21] . Lower CD4 + T-cell count (<200 cells/µl) was one of several predictors for the development of anaemia in individuals receiving zidovudine as part of their ART regimen [22] . In addition, nadir CD4 + T-cell count has been associated with an increased incidence of lipoatrophy among HIV-infected patients [23] , whereas lower increases in CD4 + T-cell count from baseline have been found to be associated with an increased risk of hepatic decompensation in patients with HIV-HCV coinfection [24] . Initiation of ART has been associated with a lower incidence of HIV type-1 (HIV-1)-associated nephropathy [25] . By contrast, higher CD4 + T-cell count at the start of ART has been identified as a risk factor for drug-limiting toxicity [26] ; thus, in order to minimize toxicity, different regimens might be preferable in patients with low CD4 + T-cell counts.
The CNS is a major reservoir of latent HIV-1 [27] and therefore represents an important target for ART. Different classes of antiretroviral drugs appear to penetrate the CNS to differing degrees [28] [29] [30] . This might become a significant consideration in some late-presenting patients, particularly those who show signs of CNS disease. In general, protease inhibitors (PIs) show poor penetration and are actively removed from the CNS by P-glycoprotein (indinavir is an exception to this class effect because it has a lesser degree of protein binding) [29] . NRTIs appear to penetrate the CNS to a greater degree than non-nucleoside reverse transcriptase inhibitors (NNRTIs) or PIs, although they are actively removed by probenecid efflux transport. NNRTIs are detectable in the CNS and are highly active, but their CNS access might be limited by protein binding. A recently proposed algorithm to assess antiretroviral CNS availability takes account of pharmacokinetic, pharmacodynamic, chemical and clinical characteristics of drugs [31] . When the resulting CNS penetration effectiveness rank score was related with cerebrospinal fluid viral load, lower CNS penetration effectiveness ranks were found to be associated with detectable cerebrospinal fluid viral load even after adjusting for total number of antiretroviral drugs, antiretroviral drug adherence, plasma viral load, CD4 + T-cell count, treatment duration and type of current regimen [31] . However, although such factors might require clinical consideration, some authors believe that CNS penetration should not influence drug choice in patients who have advanced disease but no signs of AIDS dementia [18] .
Poorer adherence to ART among very late-presenters -defined (as discussed in [1] ) as those presenting with 'advanced HIV disease', that is, a CD4 + T-cell count <200 cells/µl or with an AIDS-defining condition [32] [33] [34] [35] -has been found to be associated with long-term suboptimal treatment outcomes [36] . In a retrospective study, non-adherence was assessed by a self-administered questionnaire among 235 patients attending an outpatient unit in Rome (Italy), who had presented late and subsequently received ART for at least 4 years. A number of non-adherence patterns were defined, including less than full dose taken in the past week, timing deviation in dosing and drug holidays; all were significantly associated with poorer immunovirological outcome, and the more patterns reported by an individual patient, the less likely that patient was to experience optimal immunovirological outcome (odds ratio for each, one more non-adherence deviation =0.60 [0.47−0.77]; P<0.0001) [36] . Consequently, it is particularly important to assess late-presenting patients for possible resistance to commonly used antiretroviral drugs. In a study of untreated HIV-1-infected individuals from 1996 to 2002, 10.4% (95% CI 9.1-11.7) of ART-naive patients in Europe carried HIV-1 with one or more resistance mutations [37] . A similar prevalence of primary HIV drug resistance, 9% (95% CI 7.1-10.9) was reported from a prospective multicentre study of 831 treatment-naive HIV-1-infected patients in Germany [38] . Resistance was primarily to NRTIs, at approximately 7.6%, with fewer patients exhibiting resistance to PIs (2.5%) or NNRTIs (2.9%). Such transmitted resistance is of concern; in addition, patients who present late are more likely to carry a virus that has lost acquired mutations and reverted to the wild-type genotype. Resistance profiling before treatment initiation is thus recommended in order to help identify appropriate combinations of ART [18, 39] . Finally, individuals should be evaluated for coinfection with viral hepatitis B and/or C, and possible psychiatric disorders, drug use or socioeconomic problems, as these will all influence therapy options, drug-related side effects, likelihood of adherence to drug regimens and, ultimately, the success of treatment [8] .
Options for management
As a result of the considerations discussed above, treatment options for late presenters might be more limited than for recently infected patients, and will need to be carefully tailored to individual circumstances. The choice of initial HIV treatment should reflect patient characteristics, the results of resistance testing and the complexity of concomitant disease.
For patients who initiate treatment at CD4 + T-cell counts <350 cells/µl, a systematic review of studies with triple combination ART, which included 53 trials that enrolled a total of 14,264 patients into 90 treatment arms, found that the best virological suppression was offered by NNRTI and boosted PI-containing regimens [40] . No such analysis is available for patients who initiate treatment at CD4 + T-cell counts <200 cells/µl; however, results from some individual trials provide guidance.
A comparison of regimens involving once-daily or twice-daily dosing of ritonavir-boosted lopinavir found that the once-daily regimen was non-inferior to the twice-daily regimen in both patients with baseline CD4 + T-cell counts <50 cells/µl and in patients with baseline CD4 + T-cell counts <200 cells/µl [41] . In one study of very late-presenting patients (CD4 + T-cell levels <200 cells/µl) [32] [33] [34] [35] , efavirenz-based regimens had significantly greater virological efficacy than lopinavir/ritonavir-based regimens, but produced a slightly smaller rise in CD4 + T-cell counts [42] . In the randomized comparative 48-week ARTEMIS trial in treatment-naive patients, similar proportions of patients with baseline CD4 + T-cell counts >200 cells/ µl achieved a viral load <50 copies/ml when receiving once-daily ritonavir-boosted darunavir or once-daily ritonavir-boosted lopinavir, whereas at lower baseline CD4 + T-cell levels, a greater proportion of patients achieved a virological response in the darunavir/ ritonavir group than in the lopinavir/ritonavir group [43] . The randomized comparative CASTLE study also identified a difference in virological response at lower CD4 + T-cell counts for different PIs (plus tenofovir/ emtricitabine) in ART-naive individuals [44] . After 48 weeks, lower baseline CD4 + T-cell counts were significantly associated with lower virological response rates for lopinavir/ritonavir but not atazanavir/ritonavir (Figure 2A ). In the ARTEMIS study, at the 48-week primary end point, the greatest numeric difference was seen in patients with CD4 + T-cell levels <50 cells/µl ( Figure 2B ) [43] . However, this did not reach statistical significance until 96 weeks (79% versus 65%, respectively; P=0.009) [45] .
If resistance to a particular class or individual drug is apparent, an alternative will be required. A drug with a high genetic barrier to resistance is an important inclusion in the ART regimen when a patient's resistance profile is unknown. In addition, in late-presenting patients, treatment should not be delayed by waiting for the results of a resistance test [32] . As boosted PIcontaining combination antiretroviral regimens appear to be associated with the development of significantly less resistance at virological failure than NNRTIcontaining combination antiretroviral regimens [46] , they might be the preferred choice for patients for whom a genotypic test has not been, or cannot be, carried out in time. Indeed, the European AIDS Clinical Society advocates such an approach [39] . If virological suppression can be achieved and maintained in the long-term, the prognostic disadvantages associated with late presentation might disappear. In an analysis of 3,491 patients included in the UK CHIC study, although those who started ART at CD4 + T-cell counts <100 cells/µl and maintained virological suppression had lower absolute median CD4 + T-cell counts at 4 years than patients who started at higher CD4 + T-cell counts, they saw greater increases in CD4 + T-cell count over the period covered by the study [47] . AIDS-defining condition [32, 35] . However, the clinical challenges associated with late presentation mean that the choice of antiretroviral regimen should be carefully considered, particularly in patients who present very late with a CD4 + T-cell count <200 cells/µl (advanced HIV disease) [32] [33] [34] [35] . In particular, selection of antiretroviral drugs must take account of the full spectrum of potential drug-drug interactions and consider the toxicity risks associated with the use of antiretroviral drugs in late-presenting patients.
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